BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it
has been investigated as a druggable target of tyrosine kinase inhibitors (TKIs) over two …

Chronic myeloid leukemia (CML) results from the reciprocal translocation between the long
arms of chromosomes 9 and 22. The translocation, t (9; 22)(q34; q11. 2) is referred to as the …

In patients with chronic myeloid leukemia (CML), use of the BCR–ABL1-specific tyrosine
kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib has greatly improved patient survival …

The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …

Tyrosine kinases are proteins involved in physiological cell functions including proliferation,
differentiation, and survival. However, the dysregulation of tyrosine kinase pathways occurs …

The introduction of the BCR–ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis)
revolutionized the treatment of chronic myeloid leukaemia (CML). However, most patients …

Targeted therapy with the Abl kinase inhibitor imatinib has markedly improved the outlook
for patients with chronic myeloid leukemia (CML). Breakpoint cluster region (Bcr)-Abl …

The advent of tyrosine kinase inhibitors (TKIs) has ushered in a new era in the management
of chronic myelogenous leukemia (CML). Imatinib, the first TKI to be approved for the …

Chronic myelogenous leukaemia (CML) is a progressive and often fatal haematopoietic
neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major …

Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …